Related Experiment Videos
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jennifer L Crombie1, Austin I Kim1, Robert Redd1
1Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA.
Background:
Preclinical data support the combination of venetoclax and copanlisib in specific genomic subgroups of diffuse large B-cell lymphoma (DLBCL).
Patients And Methods:
In this investigator-initiated, phase I, multicenter trial we aimed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of copanlisib and venetoclax in patients with relapsed/refractory (R/R) DLBCL. Key eligibility criteria included relapse after or noncandidate for autologous stem cell transplantation or chimeric antigen receptor T-cell therapy and adequate hematologic and organ function. Key exclusion criteria were poorly controlled hypertension or diabetes.
Results:
A total of 12 patients enrolled using a 3 + 3 design. The median age was 62 years (range 24-87 years) and 83% were male. The median number of prior treatments was 6 (range 1-11) and 10 patients had received prior CAR T-cell therapy. There were no dose limiting toxicities (DLT)s in dose level (DL)+2. Half of patients (2/4) in DL+3 were not able to escalate to 800 mg of venetoclax due to neutropenia and nonadherence. Key hematologic toxicities included neutropenia (50%, all grade (G) 3/4) and thrombocytopenia (42%, 17% ≥ G3), and the most common nonhematologic toxicities included nausea (33%, 8% ≥ G3), diarrhea (25%, all G1/2), elevated alkaline phosphatase (25%, 8% ≥ G3), fatigue (25%, all G1/2), and headache (25%, all G1/2). One patient had a complete response lasting 3 months. The median overall survival and progression-free survival were 4.1 and 1.6 months, respectively.
Conclusion:
Although the combination was tolerable, efficacy was poor in this unselected, heavily pretreated population.
Related Concept Videos
Treatment Resistent Cancers
Clinical Trials: Overview
Treatment Resistant Cancers
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...